Financings Of The Fortnight: More IPOs But More Haircuts As Well
This article was originally published in The Pink Sheet Daily
Executive Summary
Initial public offerings by life sciences companies spanned the alphabet over the past two weeks, but each of three IPOs had one common factor - significant discounts in opening share prices.
You may also be interested in...
Lilly And Investors Spin Out Xigris To Form New Critical Care Company BioCritica
Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.
Lilly And Investors Spin Out Xigris To Form New Critical Care Company BioCritica
Initial focus of the private biotech will be on continued development and commercialization of Xigris for sepsis; investment backers are NovaQuest Capital and Care Capital.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010
During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.